Allogeneic haematopoietic stem cell transplantation for advanced stage mycosis fungoides and Sézary syndrome: never-late, never-never?

Prince, H. Miles; Abeyakoon, Chathuri

doi:10.1038/s41409-020-01150-4

Cited by 3 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although alloSCT is the only curative treatment option for patients with SS, 23 , 35 , 36 , 37 , 38 only 13.5% of this cohort received this treatment. This likely reflects the risks of significant treatment-related morbidity and mortality that precludes the majority of patients with SS with advanced age or comorbidities from accessing this treatment.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies

Campbell,

Dobos,

Haider

et al. 2023

Blood Advances

Self Cite

View full text Add to dashboard Cite

Despite increasing availability of therapies, patients with Sezary syndrome (SS) commonly endure multi-line treatment journeys, mostly with partial responses of short duration. Measuring clinical benefit is challenging; time-to-next-treatment (TTNT) provides a robust, objective measurement of efficacy. This international observational study, from three quaternary centers, examines patterns of clinical care and therapeutic benefit as measured by TTNT. TTNT was calculated for monotherapies and combination therapies, with consideration given to treatment line. 178 patients with SS (73% de novo, 27% secondary) were included, receiving 721 lines of systemic therapy, with median follow-up of 56.9 months. Across all lines, 58 different therapeutic regimens were prescribed (54 were systemic therapies), and classified into 17 treatment groups. First-line, the most common treatments were extracorporeal photopheresis (ECP)-containing combination therapy (20%) and retinoid monotherapy (19%). Median TTNT for all first-line therapies was short (5.4 months). First-line, combination therapies had longer median TTNT than monotherapies: 10.0 vs 5.0 months (p=0.004), respectively. Later delivery of combination therapies was associated with shorter clinical benefit, with median TTNT reduced to 6.2 and 2.2 months for midline (2nd-4th line) and late line (>4th line), respectively (p<0.001). First-line, ECP-containing treatments were associated with longer median TTNT compared to non ECP-containing treatments: 9.0 vs 4.9 months (p=0.007). For both ECP-monotherapy and ECP-containing combination therapy, significant reductions in TTNT were seen in later lines. These data suggest therapeutic benefit from first-line delivery of combination therapy for patients with SS, and favor early inclusion of ECP in the treatment algorithm for those who can access it.

show abstract

Section: Discussionmentioning

confidence: 96%

“…However, given the increasing availability of monoclonal antibody–based treatments and the ongoing development of novel therapies, the dilemma of optimal treatment sequencing of alloSCT remains unresolved. 35 …”

Section: Discussionmentioning

confidence: 99%